Skip to main content
Loading

First Wave BioPharma, Inc.

Tuesday, February 27, 2024
Plymouth
Gastrointestinal
First Wave BioPharma is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company is currently advancing a therapeutic development pipeline with multiple late-stage clinical programs built around three proprietary technologies – the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency; capeserod, a selective 5-HT4 receptor partial agonist which First Wave will pursue for gastrointestinal (GI) indications; and niclosamide, an oral small molecule with anti-inflammatory properties for patients with inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease. First Wave BioPharma is headquartered in Boca Raton, Florida. For more information visit www.firstwavebio.com.
Speakers
James Sapirstein, President, Chairman, and CEO - First Wave BioPharma, Inc.

State

Florida

Country

United States

Website

https://www.firstwavebio.com/

CEO/Top Company Official

James Sapirstein

Lead Product in Development

Capeserod

Development Phase of Primary Product

Phase II

Number Of Unlicensed Products

Three, - Capeserod - Adrulipase - Niclosamide
Testimonials

Double Helix


 

Supporting Bank Sponsor


 

Premier Sponsors

Conference Sponsors


 

Media Partner


 

Sign up for updates

Stay up-to-date on the BIO CEO and Investor Conference via email.

SIGN UP